neurocare group AG

We are thrilled to be attending the DGPPN Congress in Berlin this week, from November 27 to 30! This premier event by the Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. is a hub of innovation and exchange in mental health care, in Germany. This year follows the motto “Sleep Challenges of The Time” We are proud to showcase our leading solutions in TMS, EEG, tES, and our best practice platform. Many of our product and software solutions already offer innovating therapeutic benefit addressing the role of sleep and mental health. Our colleagues Ines Mynttinen and Katharina K. have also lended their expertise to the running of practical workshops throughout the event. We’ve had a fantastic week so far engaging with esteemed friends and partners in psychiatry, psychotherapy, and neuroscience. Come visit the team at booth #58 #DGPPN2024 #MentalHealthInnovation #TMS #EEG #Neurofeedback #tES

#Depression and #anxiety are among the leading challenges faced by #adolescents and young adults today. While treatments like psychotherapy and medication are effective for many, they are not universally successful, and some young people require alternative options. Transcranial Magnetic Stimulation (#TMS), a non-invasive brain stimulation therapy, has long been recognized as an effective treatment for adults with Major Depressive Disorder (#MDD). However, its use in younger populations has been limited due to concerns about its effects on developing brains. A research project presented by a team led by Dr Paul Croarkin from the Mayo Clinic sheds new light on this question, which we summarize in this article 👇 And well done to the team who carried out this research for their fantastic contribution to the field 👏 #TranscranialMagneticStimulation #MentalHealth #HealthcareInnovation #Neurostimulation #Neuroscience #Neuromodulation #rTMS #MentalHealthMatters #Mentalhealthsupport #Mentalillness #Therapy #Mentalhealthawareness #teenmentalhealth https://lnkd.in/eeK3bwy4

🚀 We have fantastic news to share with you all. Today we announce Kevin Reeder, CFA will be joining neurocare group as Chief Financial Officer, starting January 2025. Our shareholders and those who have followed our journey closely, will know Kevin has been a valued friend and partner to our business, both as a member of our Supervisory Board and as CEO of bm|t, one of neurocare´s largest investors. Kevin has a long history in international investment management both in the US and in Europe, spanning venture capital, private equity, and publicly traded investments. Kevin joined the neurocare board at the end of 2021 and played a key role in fundraising, strategy, and M&A. He will step aside from the board to fully focus on his responsibilities as CFO, driving financial strategy and supporting neurocare’s growth initiatives. “Kevin’s appointment as CFO completes neurocare’s Global Leadership Team at a time of such exciting growth for our innovative company,” says Tom Mechtersheimer, Founder & CEO of neurocare. “Having worked closely with Kevin as a Board member, I am confident that his deep understanding of our business will enable us to drive neurocare’s growth faster right away. On a personal note, I am much looking forward to sharing my life’s professional vision and purpose with someone so energetic and equally purpose driven.” Complete statements and details can be found in the press release linked here. https://lnkd.in/e9cFP8Cw #leadership #growth #healthcare #innovation #medtech #neuromodulation #neurocare #neurocaregroup

🔔 New Episode Out Now! 🎙️   In this latest interview, Dr Phern Chern Tor Psychiatrist and Head of Neurostimulation services at the Institute of Mental Health in Singapore, joins Dr. Trevor Brown to explore the key elements of running a successful TMS service.   Dr. Tor shares his insights on managing adverse events, assessing pain tolerance, and evaluating patient suitability to ensure safety and successful outcomes. He also highlights the economic advantages of TMS in a cost-effective, stepped-care model for treatment-resistant depression.   A central focus of the conversation is the importance of the therapeutic relationship, and how starting treatment gradually can improve patient comfort and results.   Tune in for expert advice on optimizing TMS services! See the link to the video in the comments below 👇   #TMS #rTMS #MagneticStimulation #TranscranialMagneticStimlation #Neurostimulation #ClinicalCare #Psychiatry #Nursing #Psychology #MentalHealth #TMSClinic #DepressionTreatment #HealthcareProfessionals #ProfessionalSupervision #PatientDoctorRelationship #TherapeuticRelationship

🌍 Today, on World Mental Health Day 2024, we focus on the theme of Workplace Mental Health—a topic that has never been more critical. Mental health services received a record-breaking 5 million referrals in 2023, a 33% increase from 2019. And in workplaces, 17% of employees are expected to struggle with a diagnosed mental health condition this year, with an additional 38% suffering without a formal diagnosis.   While 81% of workplaces have increased their focus on mental health since the pandemic, 1 in 3 employees still feel that support is inadequate. This is where innovation in mental health care becomes essential, both in the workplace and beyond.   At neurocare, neuroplasticity is anchoring our Best Practice Platform. Neuroplasticity is our brain’s natural ability to learn and adapt and is the new paradigm in mental health and performance.  We help clinicians do an intake analysis of the brain and sleep using common psychology questionnaires. Then, based on that intake data, we integrate talk therapy with neuromodulation or other tools chosen by the clinicians, empowering them to offer their patients personalized therapy. For professionals, our platform provides all the tools that empower clinicians, such as TMS, Neurofeedback, QEEG, and related training, to choose protocols or improve sleep and neurobiology. For patients, that means personalized therapy with longer-lasting and faster outcomes addressing the underlying causes of mental illness and improving their self-regulation instead of the one-size-fits-all treatment of symptoms. This World Mental Health Day, let’s continue to advocate for mental health in the workplace and beyond, and work towards solutions that are not only effective but truly transformative. Together, we can create healthier workplaces—and healthier minds. 💡 #WorldMentalHealthDay #WorkplaceWellbeing #Neuromodulation #TMS #MentalHealthAwareness #EmployeeWellbeing #BrainHealth

We have a new episode out today in Dr. Trevor Brown's Interview Series for neurocare academy! 🎓 〰 Neurofeedback and EEG diagnostic microstates for ADHD, PTSD, and Schizophrenia with Dr. Tomas Ros 〰 Dr. Tomas Ros is a neuroscientist and EEG researcher at the Center for Biomedical Imaging at the University of Geneva in Switzerland. In this interview, he shares his groundbreaking insights into the use of #neurofeedback and #EEG microstates in diagnosing and treating various mental health disorders. Learn more about how neurofeedback protocols can be personalized to enhance treatment effectiveness for conditions like #ADHD or #schizophrenia and pioneering approaches to restore alpha brainwave activity in #PTSD patients. 🧠 This is a fascinating discussion for #neurofeedback practitioners or anyone interested in learning more about these conditions and the underlying mechanisms of the brain which can harnessed through these innovative and evidence-based techniques. 🔗 See the link in the comments to watch the full interview. #neurocare #neurocaregroup #neurofeedback #eeg #adhd #ptsd #schizophrenia #psychiatry #psychology #healthcareinnovation #mentalhealth

🚀 neurocare Receives FDA Clearance for Industry-Leading iTBS Protocol for TMS in Depression Treatment 🚀 We're pleased to announce that neurocare's industry-leading intermittent Theta Burst Stimulation (iTBS) protocol has received FDA clearance its industry-leading intermittent Theta Burst Stimulation (iTBS) protocol, available across its Apollo TMS Therapy System and other Transcranial Magnetic Stimulation systems for clinical practice. In recent years, neurocare and its TMS team in Germany have engineered an advanced technology for delivering iTBS, ensuring a consistent and efficient delivery of full stimulation power across the entire burst sequence. This offers a superior solution to other TMS systems on the market, where the pulse strength can decay with subsequent pulses, resulting in less than optimal clinical care. When being treated with an iTBS protocol on the Apollo TMS system, a patient can now receive a reliable stimulation dose that accurately reflects the parameters set by the physician. “We are excited to be able to offer this new best-in-class technology so our customers can in turn provide the best care to their patients,” said Stanford Miller, Group Executive Vice President, and Managing Director of neurocare group North American operations. “We knew it was important to give physicians the confidence in using innovative technologies like TMS, so it was a key focus area for our team to find a solution to the challenge of output power consistency in iTBS stimulation," said Dr Kerstin Häringer, Group Head of TMS technology at neurocare group, Munich, Germany. "Thanks to the dedication of our world-class engineering team, we achieved superior power consistency for our TMS systems, thereby making the iTBS protocol more reliable.” Since 2021, neurocare has built a substantial network of clinic partnerships and private physician users in the field of psychiatry across the USA. More than 175 clinics and institutions have adopted the Apollo TMS Therapy system to help the most difficult-to-treat patients they service. The Apollo is FDA-cleared as a treatment for major depression after a patient has tried and not benefited from oral antidepressant medications. Apollo TMS Therapy is a covered service by most private and public health insurance providers. 🔗 Read the full press release linked in the comments. #neurocare #neurocaregroup #MentalHealthInnovation #TMS #FDAclearance #iTBS #DepressionTreatment #HealthcareTech #HealthcareInnovation #Neurostimulation #Neuromodulation #Psychiatry

📰 A new study suggests #TMS as a treatment for #Depression, is likely to be more beneficial than trying a new antidepressant medication 💊 A recent study published in the #AmericanJournalofPsychiatry highlights a significant advancement in depression treatment: Transcranial Magnetic Stimulation (TMS) therapy may be more effective than trying another course of antidepressant medications, especially after multiple failed attempts. With nearly 300 million people worldwide battling severe depression, this finding offers a promising alternative for those who haven't found relief with traditional treatments. The study, co-authored by Dr. Iris van Oostrom from neurocare Clinics Nederland , found that patients receiving TMS experienced significantly greater reductions in depression symptoms compared to those trialing another course of antidepressant. "After 8 weeks of treatment, we found that the group that received TMS had significantly lower depression rates than the group that received medication during these 8 weeks," says Dr. van Oostrom. As TMS gains recognition in depression treatment guidelines around the world, this non-invasive therapy is becoming a beacon of hope, providing patients with more effective and personalized treatment options. 🔗 Read the full article in the link in the comments. #neurocare #neurocaregroup #bestpractice #psychiatry #psychology #antidepressants #rtms #tms #neurostimulation #neuromodulation #magneticstimulation #depressiontreatment #clinicalcare #healthcareinnovation

🧠 Celebrating a Century of EEG: From Hans Berger's Discovery to Modern Breakthroughs in Mental Health 🧠 For the past 100 years, EEG technology has revolutionized our understanding of the brain, offering invaluable insights in both research and clinical practice. From its origins with Hans Berger's first recordings in 1924 to its present-day applications in psychiatry and neurology, EEG has evolved significantly. At neurocare, we are proud to continue this legacy, advancing QEEG and Neurofeedback to empower clinicians with cutting-edge tools for personalized mental health care. Explore how EEG is shaping the future of psychiatry and psychology. In this article, we speak with neurocare's in-house EEG and Neurofeedback experts Klaus Schellhorn, Trevor Brown, Amna Ghani, and Hartmut Heinrich, who share their insights in the field. 🔗 See the link in the comments to read the article. #neurocare #neurocaregroup #Neuroscience #MentalHealth #Innovation #EEG #Neurofeedback 

🚀 Today we make an important announcement. We are very pleased to welcome Tristan de Boysson as Chairman as well as Prof. Dr. Heinrich von Pierer as a Member of the Supervisory Board for neurocare group AG. Mr. de Boysson brings over 25 years of expertise in investing and corporate leadership. He is currently a Managing Partner at TVM Capital Healthcare, a growth capital healthcare-focused private equity firm headquartered in Dubai and Singapore. His previous experience includes serving as the CEO of Amanat Holdings PJSC, the largest listed healthcare and education investment company in the MENA region. Prof. Dr. Heinrich von Pierer brings his considerable global leadership experience and network to neurocare. Beginning his career at Siemens AG in 1969, Prof. Dr. von Pierer advanced to the position of CEO of the global Siemens Group, serving from 1992 to 2005 and leading businesses in engineering, power generation, healthcare, telecommunications, and finance. Subsequently, he served as Siemens’ Chairman of the Supervisory Board. Our Founder & CEO, Tom Mechtersheimer, said, “the neurocare team is grateful to have the expertise of Mr. de Boysson and Prof. Dr. Heinrich von Pierer on our Supervisory Board. Personally, I am much looking forward to driving neurocare with Tristan de Boysson as our Chairman and am humbled to have access to the immense global business and leadership experience of Prof. Dr. von Pierer. This year marks exciting progress in terms of our new global leadership team recently announced, as well as our new supervisory board and funding which will position neurocare as a global leader in mental health.” Complete statements and details can be found in the press release linked here. #neurocare #neurocaregroup #leadership #boardannouncement #corporategovernance #businessgrowth #strategicleadership #businessleadership #executiveleadership https://lnkd.in/eiui4v99